Voximetry and Medpace Core Laboratories, a full-service core laboratory, have entered a strategic partnership aimed at enhancing radiopharmaceutical clinical trials through the integration of cutting-edge dosimetry technology and comprehensive contract research organization services, Voximetry announced recently.

“It is the right time to formalize our partnership with Medpace,” Voximetry CEO Sue Wallace said in a statement. “Together, we can set a new standard for clinical trial efficiency and excellence from protocol development through analysis of final outcomes.”

According to a release, Medpace has designated Voximetry as a preferred provider of dosimetry services for its radiopharmaceutical clinical trials.

This current agreement builds off the one the two companies established in June 2024.